Rohit Singh, MD
@RohitBanwar
Followers
550
Following
5K
Media
15
Statuses
286
Medical Oncologist, Asst Professor @UVMMedCenter; alum editorial fellow@JCO_ASCO; member @ASCOTECAG. Immuno-Oncology, thoracic Oncology, Melanoma
Vermont, USA
Joined August 2011
📚 Join us at #ASCO25 for Publication 101: Peer Review & Becoming a Successful Author.🗓️ June 2 | ⏰ 10:15–11:15 AM.📍Trainee & Early Career Lounge. Get practical tips to boost your academic writing, peer-review & publishing success!.#OncTwitter #ASCO #ASCOTECAG #UVM
0
1
5
RT @NazliDizman: 🚨Mark your calendars for the @ASCOTECAG town hall on ways to navigate #ASCO25! From logistics, to intentional planning and….
0
46
0
Navigating the J1visa waiver while building a career in HemeOnc? We wrote about the challenges, strategies, and tips for finding a heme/onc job in the U.S. on a J-1 visa — while staying true to your long-term goals. @IvyLorena_Md @ASCO @uvmvermont . #MedTwitter #Oncology #IMG.
We encourage you to check out our article on tips for finding a HemeOnc job in the U.S. while on a J1 visa. It offers practical advice from individuals who have navigated the same process! @ASCO #ASCOConnections @RohitBanwar
0
7
25
🚨 Don’t miss out on the ASCO Editorial Fellowship! 🌟 As a proud alumnus, I strongly recommend it. @JCO_ASCO @ASCO @ASCOTECAG . 📚 Learn from the experts.✍️ Valuable insights the editorial process.🌍 Expand your professional network. 🔗
ascopubs.org
0
0
10
Up to 40% of cancers are preventable with lifestyle changes: avoid tobacco, eat healthy, stay active, and regular cancer screenings. Take control of your health today. #CancerAwareness #CancerPrevention #HealthTips #EarlyDetection #Wellness.
pubmed.ncbi.nlm.nih.gov
In 2018, the authors reported estimates of the number and proportion of cancers attributable to potentially modifiable risk factors in 2014 in the United States. These data are useful for advocating...
1
1
6
“Officially board-certified in Hematology and Oncology! Grateful for the journey, the support, and the opportunity to make a difference in the lives of patients. Excited for what’s ahead! #BoardCertified #Oncology” @ASCOTECAG @ASCO @ASH_hematology #HEMEONC
10
2
113
RT @rajatthawani: Jumpstart your job search with our @ASCO Connection article! Uncover secrets for navigating your career post-fellowship.….
connection.asco.org
0
5
0
RT @rajatthawani: International Faculty: Upal Basu Roy from @LUNGevity, @RamalingamMD from @WinshipAtEmory and @GsrivastavaMD from the @US_….
0
3
0
FDA approves #Durvalumab for limited-stage #SCLC after the ADRIATIC trial shows a game-changing median OS of 55.9 months vs 33.4 months! A new standard of care. #LungCancer #Oncology #lcsm
fda.gov
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
1
2
14
RT @jennifermarksmd: If you’re available at 11 am ET tomorrow, we’d love to have you join the discussion: . #lcam….
0
3
0
RT @QasimHussainiMD: From fee-for-service to value-based care—in the final hr of #ASCOQLTY24, we discussed how the future of care delivery….
0
5
0
#Osimertinib, FDA-approved for stage-III EGFR-mNSCLC after chemoXRT, #LAURA Ph-III trial. Remarkable PFS of 39.1 months compared to 5.6 months with a HR of 0.16. The 2-year PFS; 65% vs 13%, along with enhanced CNS PFS. Grade ≥3 AE 35% vs 12%. #LungCancer #CancerResearch
0
2
14
RT @doclauravater: New data: Most doctors take less than 3 weeks of vacation a year, and 70% work while on vacation. Both factors were asso….
0
256
0
RT @StephenVLiu: FDA approves subcutaneous form of atezolizumab for use where IV already approved (including NSCLC and SCLC). Based on IMsc….
targetedonc.com
The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.
0
32
0